Business
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia
HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled “Treatment of Cachexia Using Fibroblast Cells and Product
About this update from Fibrobiologics, Inc.
[{"type":"image","alt":"FibroBiologics, Inc.","displaySize":"","headline":null,"caption":"FibroBiologics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":77,"url":"https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xw_QEbMhw7ViThavcOHCOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ea452943381e269d15ec4a2f87674425","width":300,"height":77}},"lazy":false},{"type":"text","content":"HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the Canadian Intellectual Property Office has issued Canadian Patent No. 3118732, titled “Treatment of Cachexia Using Fibroblast Cells and Products Thereof.” This patent strengthens FibroBiologics’ intellectual property portfolio and underscores the Company’s commitment to advancing innovative therapies for debilitating conditions like cachexia.","length":701,"tagName":"p"},{"type":"text","content":"Cachexia, a complex metabolic syndrome characterized by severe weight loss, muscle wasting, and inflammation, often accompanies chronic diseases such as cancer, HIV/AIDS, and chronic obstructive pulmonary disease. The cachexia market for cancer is projected to hit $3.2B by 2032. The newly issued patent covers methods and compositions for treating cachexia or related inflammation through the administration of fibroblasts, providing a novel approach to addressing this unmet medical need.","length":490,"tagName":"p"},{"type":"text","content":"Key components of the patent include:","length":37,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"The use of immune-modulating fibroblasts, which are cultured under specific conditions to enhance their ability to suppress inflammation and address the root cause of cachexia and associated inflammatory mediators such as C-reactive protein, Interleukin-1, Interleukin-6, and TNF-alpha.","length":286,"tagName":"p"}]},{"val":[{"type":"text","content":"Composition of matter claims on fibroblasts that express dete...